Targeting Cancer Drug Resistance is the world's only commercially focused meeting that specifically addresses your priorities in understanding and overcoming mechanisms of cancer drug resistance.

The agenda has been carefully designed by experts from the likes of GSK, Bristol-Myers Squibb, Gilead and MD Anderson, Harvard Medical School and Massachusetts General Hospital. These industry leaders are focused on overcoming the key barriers currently preventing better drugs for cancer patients and they are coming to our meeting to share their knowledge and experience with you. Leave this meeting armed with information to nurture the therapies, that you are investing in, and delay or overcome cancer drug resistance.